These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 753493)

  • 1. A new urinary test for stone "activity".
    Hallson PC; Rose GA
    Br J Urol; 1978 Dec; 50(7):442-8. PubMed ID: 753493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystalluria in normal subjects and in stone formers with and without thiazide and cellulose phosphate treatment.
    Hallson PC; Rose GA
    Br J Urol; 1976; 48(7):515-24. PubMed ID: 13904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on crystalluria in calcium oxalate stone formers.
    Ahlstrand C; Tiselius HG; Larsson L
    Urol Res; 1984; 12(2):103-6. PubMed ID: 6539984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of calcium oxalate crystalluria on renal and vesical urines in stone formers and normal subjects.
    Robert M; Boularan AM; Delbos O; Guiter J; Descomps B
    Urol Int; 1998; 60(1):41-6. PubMed ID: 9519420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazides reduce brushite, but not calcium oxalate, supersaturation, and stone formation in genetic hypercalciuric stone-forming rats.
    Bushinsky DA; Asplin JR
    J Am Soc Nephrol; 2005 Feb; 16(2):417-24. PubMed ID: 15647340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary oxalate in summer and winter in normal subjects and in stone-forming patients with idiopathic hypercalciuria, both untreated and treated with thiazide and/or cellulose phosphate.
    Hallson PC; Kasidas GP; Rose GA
    Urol Res; 1976; 4(4):169-73. PubMed ID: 1020068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The definition of the mechanism of hypercalciuria is necessary for the treatment of recurrent stone formers.
    Pak CY; Nicar M; Northcutt C
    Contrib Nephrol; 1982; 33():136-51. PubMed ID: 6749417
    [No Abstract]   [Full Text] [Related]  

  • 8. Calcium stone disease: an overview.
    Goldwasser B; Weinerth JL; Carson CC
    J Urol; 1986 Jan; 135(1):1-9. PubMed ID: 3510312
    [No Abstract]   [Full Text] [Related]  

  • 9. Measurement of calcium phosphate crystalluria: influence of pH and osmolality and invariable presence of oxalate.
    Hallson PC; Rose GA
    Br J Urol; 1989 Nov; 64(5):458-62. PubMed ID: 2611613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic treatment of renal calcium stones. Experiences with dietary advice, cellulose, phosphate and thiazides.
    Ljunghall S; Backman U; Danielson BG; Fellström B; Johansson G; Wikström B
    Scand J Urol Nephrol Suppl; 1980; 53():239-52. PubMed ID: 6938001
    [No Abstract]   [Full Text] [Related]  

  • 11. Nephrolithiasis: recent advances in therapy.
    Erwin DT
    South Med J; 1976 Jul; 69(7):935-7. PubMed ID: 941065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated levels of supersaturation with calcium phosphate and calcium oxalate in the distal tubule.
    Tiselius HG
    Urol Res; 1997; 25(2):153-9. PubMed ID: 9144885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of urine composition and calcium salt crystallization properties in standardized volume-adjusted 12-h night urine from normal subjects and calcium oxalate stone formers.
    Bek-Jensen H; Tiselius HG
    Urol Res; 1997; 25(5):365-72. PubMed ID: 9373919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial crystalluria determination and the risk of recurrence in calcium stone formers.
    Daudon M; Hennequin C; Boujelben G; Lacour B; Jungers P
    Kidney Int; 2005 May; 67(5):1934-43. PubMed ID: 15840041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of urine oxalate during long-term thiazide therapy in patients with calcium urolithiasis.
    Cohanim M; Yendt ER
    Invest Urol; 1980 Sep; 18(2):170-3. PubMed ID: 7410033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystallization properties in urine from calcium oxalate stone formers.
    Tiselius HG; Bek-Jensen H; Fornander AM; Nilsson MA
    J Urol; 1995 Sep; 154(3):940-6. PubMed ID: 7637098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etiopathogenesis, clinical manifestations, and management of canine calcium oxalate urolithiasis.
    Osborne CA; Poffenbarger EM; Klausner JS; Johnston SD; Griffith DP
    Vet Clin North Am Small Anim Pract; 1986 Jan; 16(1):133-70. PubMed ID: 3518199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the risk of stone formation: study on crystalluria in patients with recurrent calcium oxalate urolithiasis.
    Robert M; Boularan AM; Delbos O; Monnier L; Grasset D
    Eur Urol; 1996; 29(4):456-61. PubMed ID: 8791054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of crystalluria as a method of evaluation of preventive medical treatment of renal calculosis].
    Buli P; Pulini V; Platania A; Petrone U; Brunocilla E; Martorelli M
    Minerva Urol; 1982; 34(3):137-50. PubMed ID: 7177065
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in vitro in the urine of healthy controls and stone-forming patients.
    Atmani F; Khan SR
    Urol Int; 2002; 68(1):54-9. PubMed ID: 11803269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.